Stroke after transcatheter aortic valve replacement: A severe complication with low predictability.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
05 2022
Historique:
revised: 25 01 2022
received: 16 03 2021
accepted: 16 02 2022
pubmed: 22 3 2022
medline: 18 5 2022
entrez: 21 3 2022
Statut: ppublish

Résumé

We aimed to describe stroke and transient ischemic attacks (TIAs) after transcatheter aortic valve replacement (TAVR) and to identify associated risk factors. Stroke/TIA after TAVR is a major complication. A total of 1919 concomitant patients underwent TAVR in a single center from 2007 to 2017. Pre-, intra-, and postprocedural data were collected prospectively in a database and analyzed retrospectively. Stroke and TIA were documented according to the Valve Academic Research Consortium-II criteria. Logistic regression was used to determine risk factors for stroke after TAVR. Mean age was 79.5 ± 6.8 years, mean logistic EuroScore was 17.6% ± 12.8%, and 51.8% (n = 994) of the patients were female. Stroke/TIA occurred in 76 patients (3.9%), 1.9% were disabling, and 1.6% nondisabling. The predominant type of stroke were territorial ischemic lesions (82.4%), with primary bleeding in 4.4% and border zone infarctions in 4.4%. Left-sided lesions were more common (45.6% left sided vs. 25% right sided) and 13.2% of the lesions were bilateral (4.4% no finding and 11.8% missing data). In multivariate logistic regression, prior stroke (odds ratio [OR] = 1.83, p = 0.046) and initial experience (first 300 TAVR implanted at our center) were identified as independent risk factors for stroke/TIA during the first 30 days (OR = 1.95, p = 0.045). Overall, the occurrence of stroke had a highly significant impact on a 30-day mortality (13.2% vs. 4.9% in patients without stroke (p = 0.005). Stroke within the first 30 days after TAVR severely impairs 30-day survival. We identified prior stroke and initial experience as significant independent risk factors for the occurrence of stroke after TAVR.

Sections du résumé

OBJECTIVES
We aimed to describe stroke and transient ischemic attacks (TIAs) after transcatheter aortic valve replacement (TAVR) and to identify associated risk factors.
BACKGROUND
Stroke/TIA after TAVR is a major complication.
METHODS
A total of 1919 concomitant patients underwent TAVR in a single center from 2007 to 2017. Pre-, intra-, and postprocedural data were collected prospectively in a database and analyzed retrospectively. Stroke and TIA were documented according to the Valve Academic Research Consortium-II criteria. Logistic regression was used to determine risk factors for stroke after TAVR.
RESULTS
Mean age was 79.5 ± 6.8 years, mean logistic EuroScore was 17.6% ± 12.8%, and 51.8% (n = 994) of the patients were female. Stroke/TIA occurred in 76 patients (3.9%), 1.9% were disabling, and 1.6% nondisabling. The predominant type of stroke were territorial ischemic lesions (82.4%), with primary bleeding in 4.4% and border zone infarctions in 4.4%. Left-sided lesions were more common (45.6% left sided vs. 25% right sided) and 13.2% of the lesions were bilateral (4.4% no finding and 11.8% missing data). In multivariate logistic regression, prior stroke (odds ratio [OR] = 1.83, p = 0.046) and initial experience (first 300 TAVR implanted at our center) were identified as independent risk factors for stroke/TIA during the first 30 days (OR = 1.95, p = 0.045). Overall, the occurrence of stroke had a highly significant impact on a 30-day mortality (13.2% vs. 4.9% in patients without stroke (p = 0.005).
CONCLUSION
Stroke within the first 30 days after TAVR severely impairs 30-day survival. We identified prior stroke and initial experience as significant independent risk factors for the occurrence of stroke after TAVR.

Identifiants

pubmed: 35312220
doi: 10.1002/ccd.30143
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1897-1905

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68(7):673-684.
Agarwal S, Garg A, Parashar A, et al. In-hospital mortality and stroke after surgical aortic valve replacement: a nationwide perspective. J Thorac Cardiovasc Surg. 2015; 150(3):571-578. https://doi.org/10.1016/j.jtcvs.2015.05.068
Werner N, Zeymer U, Schneider S, et al. Incidence and clinical impact of stroke complicating transcatheter aortic valve implantation: results from the German TAVI Registry. Catheter Cardiovasc Interv. 2016;88(4):644-653.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607. https://doi.org/10.1056/NEJMoa1008232
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609-1620.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706-1715.
Kapadia SR, Huded CP, Kodali SK, et al. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER Trial. J Am Coll Cardiol. 2018; 72(20):2415-2426.
Huded CP, Tuzcu EM, Krishnaswamy A, et al. Association between transcatheter aortic valve replacement and early postprocedural stroke. JAMA. 2019;321(23):2306-2315.
Bleiziffer S, Ruge H, Mazzitelli D, et al. Valve implantation on the beating heart: catheter-assisted surgery for aortic stenosis. Dtsch Arztebl Int. 2009;106(14):235-241.
Lange R, Bleiziffer S, Mazzitelli D, et al. Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future. J Am Coll Cardiol. 2012;59(3):280-287.
Bleiziffer S, Mazzitelli D, Opitz A, et al. Beyond the short-term: clinical outcome and valve performance 2 years after transcatheter aortic valve implantation in 227 patients. J Thorac Cardiovasc Surg. 2012;143(2):310-317.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(5):S45-S60.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12):1373-1379.
Athappan G, Gajulapalli RD, Sengodan P, et al. Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature. J Am Coll Cardiol. 2014;63(20):2101-2110.
Fanning JP, Wesley AJ, Walters DL, et al. Topographical distribution of perioperative cerebral infarction associated with transcatheter aortic valve implantation. Am Heart J. 2018;197:113-123.
Thirumala PD, Muluk S, Udesh R, et al. Carotid artery disease and periprocedural stroke risk after transcatheter aortic valve implantation. Ann Card Anaesth. 2017;20(2):145-151.
Conrotto F, D'Ascenzo F, D'Onofrio A, et al. Predictive ability of the CHADS2 and CHA2DS2-VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. Eur J Cardiothorac Surg. 2016;50(5):867-873.
Vlastra W, Jimenez-Quevedo P, Tchétché D, et al. Predictors, incidence, and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke. Circ Cardiovasc Interv. 2019;9:007546.
Kleiman NS, Maini BJ, Reardon MJ, et al. Neurological events following transcatheter aortic valve replacement and their predictors: a report from the CoreValve Trials. Circ Cardiovasc Interv. 2016;9(9):e003551.
Oliveira-Filho J, Massaro AR, Yamamoto F, Bustamante L, Scaff M. Stroke as the first manifestation of calcific aortic stenosis. Cerebrovasc Dis. 2000;10(5):413-416.
Khetarpal V, Mahajan N, Madhavan R, et al. Calcific aortic valve and spontaneous embolic stroke: a review of literature. J Neurol Sci. 2009;287(1-2):32-35.
Didier R, Koifman E, Kiramijyan S, et al. The impact of prior stroke on the outcome of patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Cardiovasc Revasc Med. 2016;17(5):322-327.

Auteurs

Lena K Eschenbach (LK)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Magdalena Erlebach (M)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Marcus-André Deutsch (MA)

Clinic for Thoracic and Cardiovascular Surgery, Herz-und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Hendrik Ruge (H)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Sabine Bleiziffer (S)

Clinic for Thoracic and Cardiovascular Surgery, Herz-und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Lisa Holzer (L)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Markus Krane (M)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.
DZHK (German Centre for Cardiovascular Research)-Partner site Munich Heart Alliance, Munich, Germany.

Stephanie Voss (S)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Ruediger Lange (R)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.
DZHK (German Centre for Cardiovascular Research)-Partner site Munich Heart Alliance, Munich, Germany.

Melchior Burri (M)

Department of Cardiovascular Surgery, German Heart Centre Munich, Technische Universität, München, Germany.
Department of Cardiovascular Surgery, German Heart Centre Munich, Insure (Institute for Translational Cardiac Surgery), Technische Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH